[go: up one dir, main page]

DK2327766T3 - Nitrilaser - Google Patents

Nitrilaser Download PDF

Info

Publication number
DK2327766T3
DK2327766T3 DK10190397.9T DK10190397T DK2327766T3 DK 2327766 T3 DK2327766 T3 DK 2327766T3 DK 10190397 T DK10190397 T DK 10190397T DK 2327766 T3 DK2327766 T3 DK 2327766T3
Authority
DK
Denmark
Prior art keywords
acid
sequence
polypeptide
sequences
nucleic acid
Prior art date
Application number
DK10190397.9T
Other languages
English (en)
Inventor
Jennifer Ann Chaplin
David Paul Weiner
Aileen Milan
Ellen Chi
Jay M Short
Mark Madden
Mark Burk
Dan Robertson
Grace Desantis
Original Assignee
Basf Enzymes Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Enzymes Llc filed Critical Basf Enzymes Llc
Application granted granted Critical
Publication of DK2327766T3 publication Critical patent/DK2327766T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/002—Nitriles (-CN)
    • C12P13/004—Cyanohydrins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/006—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by reactions involving C-N bonds, e.g. nitriles, amides, hydantoins, carbamates, lactames, transamination reactions, or keto group formation from racemic mixtures
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/42—Hydroxy-carboxylic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Processing Of Solid Wastes (AREA)
  • Treatment Of Sludge (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Claims (17)

1. Isoleret, syntetisk eller rekombinant nukleinsyre indeholdende (a) en nukleinsyresekvens, der har mindst 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% eller mere, eller 100% sekvensidentitet med SEQ ID NO: 189 og kodende for et polypeptid med en nitrilaseaktivitet, hvor nukleinsyren koder for mindst ét polypeptid med en nitrilaseaktivitet; eller (b) en nukleinsyresekvens, der er fuldstændigt komplementærtil (a).
2. Ekspressionskassette, vektor eller kloningsmedium indeholdende en nukleinsyre omfattende en sekvens som angivet i krav 1.
3. Transformeret celle omfattende (i) en nukleinsyre med en sekvens som angivet i krav 1 eller en ekspressionskassette, en vektor eller et kloningsmedium som angivet i krav 2; (ii) den transformerede celle af (i), hvor cellen er (a) en gramnegativ bakterie, en grampositiv bakterie eller en monocellulær eukaryotisk organisme; (b) en Escherichia coli; (c) en Streptomyces diversa, Lactobacillus gasseri, Lactococcus lactis, Lactococcus cremoris eller en Bacillus subtilis; eller (d) en Saccharomyces cerevisiae, Schizosaccharomyces pombe, Pichia pastoris, Kluyveromyces lactis, Hansenula polymorpha eller en Aspergillus niger.
4. Transgen, ikke-human organisme indeholdende en sekvens som angivet i krav 1 eller en ekspressionskassette, en vektor eller et kloningsmedium som angivet i krav 2.
5. Isoleret, syntetisk eller rekombinant polypeptid indeholdende: (a) en sekvens, der omfatter 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% eller mere, eller 100% sekvensidentitet med SEQ ID NO:190, hvor polypeptidet har en nitrilaseaktivitet; eller (b) en aminosyre kodet af nukleinsyren ifølge krav 1(a).
6. Isoleret, syntetisk eller rekombinant polypeptid ifølge krav 5, hvor nitrilaseaktiviteten omfatter (a) hydrolyse af et nitril til en carboxylsyre; (b) hydrolyse afen cyanhydrindel eller en aminonitrildel af et molekyle, hvor molekylet eventuelt indeholder (S)-2-amino-4-phenyl-butansyre, eller molekylet indeholder en L-aminosyre, eller molekylet indeholder et næringsmiddeladditiv eller et farmaceutisk lægemiddel; eller (c) en enantio-selektiv nitrilaseaktivitet, hvor den enantio-selektive aktivitet omfatter dannelse af et chiralt alfa-hydroxysyremolekyle eller et chiralt aminosyremolekyle ved katalyse af hydrolysen af et molekyle med en cyanhydrindel eller en aminonitrildel, hvor det dannede chirale molekyle eventuelt er en (R)-enantiomer eller en (S)-enantiomer.
7. Isoleret, syntetisk eller rekombinant polypeptid ifølge krav 5 eller krav 6, hvor nitrilaseaktiviteten omfatter hydrolyse af et hydroxyglutarylnitril til dannelse af en (R)-ethyl 4-cyano-3-hydroxysmørsyre, hvor polypeptidet eventuelt enantio-selektivt hydrolyserer h yd roxy g I u ta ry I n itri I et til dannelse afen (R)-enantiomer (R)-ethyl 4-cyano-3-hydroxysmørsyre, hvor polypeptidet eventuelt danner et produkt med en enantiomerrenhed omfattende en ee på mindst 95%, 96%, 97%, 98% eller 99%, og hvor hydroxyglutarylnitrilet eventuelt indeholder 1,3-di-cyano-2-hydroxy-propan eller et hydroxyglutaronitil, eller hvor hydroxyglutaronitrilet eventuelt omfatter et 3-hydroxyglutaronitril.
8. Isoleret, syntetisk eller rekombinant polypeptid ifølge krav 5 eller krav 6, hvor nitrilaseaktiviteten omfatter hydrolyse af et hydroxyglutarylnitril til dannelse af en ethyl 4-cyano-3-hydroxysmørsyre, hvor polypeptidet eventuelt enantio-selektivt hydrolyserer hydroxyglutarylnitrilet til dannelse af en (S)-enantiomer (S)-ethyl-4-cyano-3-hydroxysmørsyre, og hvor polypeptidet eventuelt danner et produkt med en enantiomerrenhed omfattende en ee på 95%, 96%, 97%, 98% eller 99%.
9. Isoleret, syntetisk eller rekombinant polypeptid ifølge krav 5 eller krav 6, hvor nitrilaseaktiviteten omfatter hydrolyse af et mandelonitril til dannelse af en mandelsyre eller et mandelsyrederivat, hvor mandelsyren eventuelt omfatter (R)-2-chlormandelsyre, hvor mandelsyren eventuelt omfatter en aromatisk ringsubstitution i ortho-, meta- eller para-stillingerne; et 1-naphthylderivat af (R)-mandelsyre, et pyridylderivat af (R) -mandelsyre eller thienylderivat af (R)-mandelsyre eller en kombination deraf, hvor mandelsyren eventuelt omfatter (S)-methyl-benzylcyanid, og mandelonitrilet omfatter (S)-methoxy-benzylcyanid, eller hvor mandelsyren eventuelt omfatter en aromatisk ringsubstitution i ortho-, meta-eller para-stillingerne; et 1-naphthylderivat af (S)-mandelsyre, et pyridylderivat af (S) -mandelsyre eller thienylderivat af (S)-mandelsyre eller en kombination deraf.
10. Isoleret, syntetisk eller rekombinant polypeptid ifølge krav 5 eller krav 6, hvor nitrilaseaktiviteten omfatter hydrolyse af et phenyllactocyanonitril til dannelse af et (S)-phenyl-mælkesyrederivat eller et (R)-phenyl-mælkesyrederivat.
11. Enzympræparat indeholdende et polypeptid som angivet i ethvert af kravene 5 til 10, hvor præparatet er et flydende eller tørt præparat.
12. Industriel fremgangsmåde omfattende anvendelse af det isolerede, syntetiske eller rekombinante polypeptid som angivet i ethvert af kravene 5 til 10 ved hydrolysen af et substrat med en cyanhydrindel eller en aminonitrildel til dannelse afen sammensætning indeholdende en alfa-hydroxysyre eller en aminosyre.
13. Industriel fremgangsmåde ifølge krav 12, hvor den industrielle fremgangsmåde yderligere omfatter: (i) fremstillingen afen farmaceutisk sammensætning indeholdende den dannede alfa-hydroxysyre eller aminosyre, (ii) fremstillingen af en kemisk forbindelse indeholdende den dannede alfa-hydroxysyre eller aminosyre, (iii) katalyse af nedbrydningen af et affaldsprodukt, hvor nedbrydningen omfatter hydrolyse af et substrat med en cyanhydrindel eller en aminonitrildel, (iv) fremstillingen af et lægemiddelmellemprodukt, hvor lægemiddelmellemproduktet omfatter den dannede alfa-hydroxysyre eller aminosyre, og hvor polypeptidet eventuelt anvendes til at hydrolysere et hydroxyglutarylnitril-substrat, (v) fremstillingen af et detergent, eller (vi) fremstillingen af et næringsmiddelprodukt.
14. Isoleret, syntetisk eller rekombinant polypeptid ifølge krav 5 kodet afen nukleinsyre udtrykt i en værtscelle, hvor værtscellen omfatter: (a) en gramnegativ bakterie, en grampositiv bakterie eller en monocellulær eukaryotisk organisme; (b) en Escherichia coli; (c) en Streptomyces diversa, Lactobacillus gasseri, Lactococcus lactis, Lactococcus cremoris eller en Bacillus subtilis; eller (d) en Saccharomyces cerevisiae, Schizosaccharomyces pombe, Pichia pastoris, Kluyveromyces lactis, Hansenula polymorpha eller en Aspergillus niger.
15. Fremgangsmåde til fremstilling af en carboxylsyre, omfattende hydrolyse af et nitril under anvendelse af det isolerede, syntetiske eller rekombinante polypeptid ifølge krav 5 eller krav 6 under vandige betingelser.
16. Polypeptid ifølge krav 5, men som mangler en signalsekvens.
17. Polypeptid ifølge krav 5, der yderligere omfatter en heterolog sekvens.
DK10190397.9T 2001-06-21 2002-05-15 Nitrilaser DK2327766T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30018901P 2001-06-21 2001-06-21
US30900601P 2001-07-30 2001-07-30
US35133602P 2002-01-22 2002-01-22
EP08075753A EP2039762A3 (en) 2001-06-21 2002-05-15 Nitralases

Publications (1)

Publication Number Publication Date
DK2327766T3 true DK2327766T3 (da) 2016-03-07

Family

ID=27404717

Family Applications (3)

Application Number Title Priority Date Filing Date
DK10190399.5T DK2327767T3 (da) 2001-06-21 2002-05-15 Nitrilaser
DK10190397.9T DK2327766T3 (da) 2001-06-21 2002-05-15 Nitrilaser
DK10189100.0T DK2327765T3 (da) 2001-06-21 2002-05-15 Nitrilaser

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK10190399.5T DK2327767T3 (da) 2001-06-21 2002-05-15 Nitrilaser

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10189100.0T DK2327765T3 (da) 2001-06-21 2002-05-15 Nitrilaser

Country Status (6)

Country Link
EP (6) EP2319919B1 (da)
JP (2) JP4405258B2 (da)
AU (2) AU2006252258B2 (da)
CA (2) CA2677781C (da)
DK (3) DK2327767T3 (da)
WO (1) WO2003000840A2 (da)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1141275B1 (en) 1999-01-05 2009-08-12 Trustees Of Boston University Improved nucleic acid cloning
US20040005673A1 (en) 2001-06-29 2004-01-08 Kevin Jarrell System for manipulating nucleic acids
US7300775B2 (en) 1999-12-29 2007-11-27 Verenium Corporation Methods for producing α-substituted carboxylic acids using nitrilases and strecker reagents
US20040002147A1 (en) * 1999-12-29 2004-01-01 Desantis Grace Nitrilases
US7521216B2 (en) 1999-12-29 2009-04-21 Verenium Corporation Nitrilases and methods for making and using them
US7608445B1 (en) 1999-12-29 2009-10-27 Verenium Corporation Nitrilases, nucleic acids encoding them and methods for making and using them
US7435562B2 (en) 2000-07-21 2008-10-14 Modular Genetics, Inc. Modular vector systems
AU2003251523A1 (en) 2002-06-13 2003-12-31 Diversa Corporation Processes for making (r)-ethyl 4-cyano-3-hydroxybutyric acid
ATE435278T1 (de) * 2003-02-27 2009-07-15 Basf Se Modifizierte nitrilasen und deren verwendung in verfahren zur herstellung von carbonsäuren
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
US7198926B2 (en) 2003-05-08 2007-04-03 E. I. Du Pont De Nemours And Company Preparation of (E)- and (Z)-2-methyl-2-butenoic acids
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
CA2590245A1 (en) 2004-11-11 2006-05-18 Modular Genetics, Inc. Ladder assembly and system for generating diversity
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
MY144906A (en) 2005-10-21 2011-11-30 Novartis Ag Human antibodies against il13 and therapeutic uses
WO2007094885A2 (en) * 2005-12-07 2007-08-23 Southern Methodist University Identification of a nitrilase from b. japonicum by rational genome mining and methods of use
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
AR060607A1 (es) 2006-04-21 2008-07-02 Novartis Ag Derivados de purina,composiciones farmaceuticas que los contienen, metodo de preparacion y usos en enfermedades obstructivas o inflamatorias de las vias respiratorias.
CN100500832C (zh) * 2006-04-29 2009-06-17 浙江工业大学 枯草芽孢杆菌zjb-063及其应用
BRPI0717564A2 (pt) 2006-09-29 2013-10-22 Novartis Ag Pirazolopirimidinas como inibidores de pi3k lipídeo cinase
US20080176901A1 (en) 2007-01-10 2008-07-24 Irm Llc Compounds and compositions as channel activating protease inhibitors
WO2008106662A2 (en) * 2007-03-01 2008-09-04 Verenium Corporation Nitrilases, nucleic acids encoding them and methods for making and using them
AU2008248598B2 (en) 2007-05-07 2011-11-17 Novartis Ag Organic compounds
ES2654395T3 (es) 2007-12-10 2018-02-13 Novartis Ag Análogos de amilorida espirocíclicos como bloqueantes de ENaC
JP5165393B2 (ja) * 2008-01-10 2013-03-21 旭化成ケミカルズ株式会社 グリコール酸又はグリコール酸アンモニウムの製造方法
JP5584138B2 (ja) 2008-01-11 2014-09-03 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
EP2300010B1 (en) 2008-06-10 2015-03-04 Novartis AG Pyrazine derivatives as epithelial sodium channel blockers
DK2391366T3 (da) 2009-01-29 2013-01-07 Novartis Ag Substituerede benzimidazoler til behandling af astrocytomer
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
JP5781510B2 (ja) 2009-08-12 2015-09-24 ノバルティス アーゲー ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
HRP20190016T1 (hr) 2009-08-17 2019-03-08 Intellikine, Llc Heterociklički spojevi i njihova upotreba
MX2012002179A (es) 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
MX2012004792A (es) 2009-10-22 2013-02-01 Vertex Pharma Composiciones para el tratamiento de fibrosis quistica y otras enfermedades cronicas.
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
JP5959541B2 (ja) 2011-02-25 2016-08-02 ノバルティス アーゲー Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン
GB201111637D0 (en) * 2011-07-07 2011-08-24 Waterford Inst Technology A process for producing amides and acids using a nitrile-metabolising enzyme
GB201111639D0 (en) * 2011-07-07 2011-08-24 Waterford Inst Technology A process for producing amides and acids using a nitrile-metabolising enzyme
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
WO2013038362A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
US9034879B2 (en) 2011-09-16 2015-05-19 Novartis Ag Heterocyclic compounds for the treatment of CF
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
CN102363775B (zh) * 2011-11-30 2014-04-02 重庆大学 一种纯化腈水解酶的方法
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
WO2013149581A1 (en) 2012-04-03 2013-10-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
HK1219421A1 (zh) 2013-03-15 2017-04-07 因特利凯有限责任公司 激酶抑制剂的组合及其用途
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2015162461A1 (en) 2014-04-24 2015-10-29 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
MX2016013812A (es) 2014-04-24 2017-03-09 Novartis Ag Derivados de amino-pirazina como inhibidores de fosfatidil-inositol-3-cinasa.
EA201692140A1 (ru) 2014-04-24 2017-04-28 Новартис Аг Производные аминопиридина в качестве ингибиторов фосфатидилинозитол 3-киназы
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
BR112017001695A2 (pt) 2014-07-31 2017-11-21 Novartis Ag terapia de combinação
CN104774825B (zh) * 2015-03-23 2017-11-07 浙江工业大学 腈水解酶突变体及其应用
WO2017085747A2 (en) * 2015-11-19 2017-05-26 Gsp Crop Science Pvt. Ltd, A novel process for the preparation of trifloxystrobin
CN106854673B (zh) * 2016-12-23 2020-05-15 枣庄市杰诺生物酶有限公司 利用腈水解酶工程菌制备r-邻氯扁桃酸的方法
CN109111043B (zh) * 2018-09-16 2021-11-09 苏州渭中科技发展有限公司 一种高盐高cod废水的处理方法
CN113614242A (zh) * 2019-01-22 2021-11-05 巴斯夫欧洲公司 4-氰基苯甲酸或其盐的生产方法
JP2022537667A (ja) 2019-06-10 2022-08-29 ノバルティス アーゲー Ｃｆ、ｃｏｐｄ、及び気管支拡張症の治療のためのピリジン及びピラジン誘導体
EP4021572A1 (en) 2019-08-28 2022-07-06 Novartis AG Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US813998A (en) 1903-10-31 1906-02-27 Rail Joint Co Insulated rail-joint.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU7791991A (en) 1990-04-24 1991-11-11 Stratagene Methods for phenotype creation from multiple gene populations
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
JP2676568B2 (ja) 1991-06-26 1997-11-17 日東化学工業株式会社 Ｒ（−）−マンデル酸およびその誘導体の製造法
US5241087A (en) 1992-03-09 1993-08-31 Bend Research, Inc. Enantiomeric enrichment of cyanohydrins
US5631280A (en) 1995-03-29 1997-05-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6030779A (en) 1995-07-18 2000-02-29 Diversa Corporation Screening for novel bioactivities
US5958672A (en) 1995-07-18 1999-09-28 Diversa Corporation Protein activity screening of clones having DNA from uncultivated microorganisms
JPH0937788A (ja) 1995-07-31 1997-02-10 Nitto Chem Ind Co Ltd 新規なニトリラーゼ遺伝子
US5965408A (en) 1996-07-09 1999-10-12 Diversa Corporation Method of DNA reassembly by interrupting synthesis
US5939250A (en) 1995-12-07 1999-08-17 Diversa Corporation Production of enzymes having desired activities by mutagenesis
DE19848129A1 (de) 1998-10-19 2000-04-20 Basf Ag Verfahren zur Herstellung chiraler Carbonsäuren aus Nitrilen mit Hilfe einer Nitrilase oder Mikroorganismen, die ein Gen für die Nitrilase enthalten
DE19929365A1 (de) 1999-06-25 2000-12-28 Basf Lynx Bioscience Ag Teilsequenzen der Gene des Primär- und Sekundärmetabolismus aus Corynebacterium glutamicum und ihr Einsatz zur mikrobiellen Herstellung von Primär- und Sekundärmetaboliten
US7300775B2 (en) * 1999-12-29 2007-11-27 Verenium Corporation Methods for producing α-substituted carboxylic acids using nitrilases and strecker reagents
US7094926B2 (en) 2000-01-25 2006-08-22 Kaneka Corporation Process for producing optically active carboxylic acid substituted in 2-position
AU2014284148B2 (en) 2013-06-21 2017-02-23 Bio-Rad Laboratories, Inc. Microfluidic system with fluid pickups

Also Published As

Publication number Publication date
CA2677781C (en) 2013-01-29
AU2006252258B2 (en) 2010-07-22
DK2327765T3 (da) 2015-07-13
EP1578910A2 (en) 2005-09-28
EP2327765B1 (en) 2015-04-01
EP2327766A1 (en) 2011-06-01
CA2677781A1 (en) 2003-01-03
EP2039762A2 (en) 2009-03-25
EP2039762A3 (en) 2009-07-29
AU2010212259B2 (en) 2012-11-29
JP2007252382A (ja) 2007-10-04
EP2319919B1 (en) 2015-08-12
AU2006252258A1 (en) 2007-01-25
CA2445046C (en) 2009-11-24
JP2005509407A (ja) 2005-04-14
EP2327765A1 (en) 2011-06-01
WO2003000840A3 (en) 2007-11-15
CA2445046A1 (en) 2003-01-03
EP2327766B1 (en) 2015-12-02
JP4405258B2 (ja) 2010-01-27
EP2327767B1 (en) 2015-04-29
AU2010212259A1 (en) 2010-09-02
DK2327767T3 (da) 2015-07-27
EP2327767A1 (en) 2011-06-01
EP2319919A1 (en) 2011-05-11
EP1578910A4 (en) 2008-06-04
JP4405528B2 (ja) 2010-01-27
WO2003000840A2 (en) 2003-01-03

Similar Documents

Publication Publication Date Title
DK2327766T3 (da) Nitrilaser
CA2486062C (en) Nitrilases, nucleic acids encoding them and methods for making and using them
US8334125B2 (en) Nucleic acids encoding nitrilases
EP2115153B1 (en) Nitrilases, nucleic acids encoding them and methods for making and using them
US20040014195A1 (en) Nitrilases, nucleic acids encoding them and methods for making and using them
AU2013200739B2 (en) Nitrilases
AU2002350008A1 (en) Nitrilases